BLX Technology Integration
Integrated Roxolid and SLActive technologies into BLX and helped position the implant system within Straumann ImmediaXy as a high-performance solution for immediate treatment protocols.
Back to portfolio
Case 07
Other examples: Product Innovation, Evidence and Regulatory Impact
A selection of additional product platforms, workflow solutions and evidence programmes shaped at Straumann — from technology integration to FDA regulatory milestones.
Straumann ImmediaXy Ecosystem
Helped shape and position Straumann ImmediaXy as an end-to-end ecosystem connecting data acquisition, treatment planning, surgery and restoration for efficient and predictable immediate treatment workflows.
Straumann ProClean Cassette
Led cross-functional development of the Straumann ProClean Cassette, translating the demanding requirements of major hospitals and Sterile Services Departments into a validated, high-spec solution for fully automated instrument reprocessing. The platform helped secure adoption across 45+ US VA hospitals and 4 Bundeswehr hospitals, opening substantial downstream implant business and contributing to 20% implant revenue growth.
SLActive Evidence in Irradiated Patients
Recognised a critical interpretation barrier in long-term SLActive evidence for head and neck irradiated cancer patients and engaged Prof. Nelson to develop a clinical clarification. Aligned Clinical, Medical and Regulatory Affairs teams around the evidence and used the resulting publication as a key submission document supporting the removal of IFU restrictions and enabling predictable implant-supported prosthetic rehabilitation for this high-risk population.
Compromised Patients: FDA Regulatory Milestone
Established medically compromised patients as a strategic evidence and differentiation platform for SLActive, leading the evidence roadmap and aligning Clinical, Medical and Regulatory Affairs around patients with Type II diabetes and those previously irradiated in the head and neck. The programme culminated in a major Regulatory Affairs milestone: FDA-cleared removal of both populations from IFU cautions and precautions, creating a unique regulatory position for Straumann and addressing significant unmet needs — including predictable implant-supported rehabilitation following oral cancer.